DNA antibody constructs and method of using same

Patent metadata

Field	Value
Publication number	US-11208470-B2
Application number	US-201816142457-A
Country	US
Kind code	B2
Filing date	Sep 26, 2018
Priority date	Dec 13, 2012
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.

First claim

What is claimed is:

1. A nucleic acid molecule encoding a synthetic antibody comprising one or more nucleic acid sequences selected from the group consisting of:
a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 67;
a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 69;
a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 71;
a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 73;
a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 75;
a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 77; and
a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 65.

2. A nucleic acid molecule encoding a synthetic antibody comprising one or more nucleic acid sequences selected from the group consisting of:
a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 68;
a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 70;
a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 72;
a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 74;
a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 76;
a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 78; and
a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 66.

3. The nucleic acid molecule of claim 1 , wherein the nucleic acid sequence encodes a light chain polypeptide, a heavy chain polypeptide, both a light chain polypeptide and a heavy chain polypeptide, or fragments thereof.

4. The nucleic acid molecule of claim 3 , wherein when the nucleic acid sequence encodes a light chain polypeptide and a heavy chain polypeptide, the nucleic acid sequence also encodes a protease cleavage site.

5. The nucleic acid molecule of claim 4 , wherein the protease cleavage site is located between the light chain polypeptide and the heavy chain polypeptide and wherein the protease cleavage site includes a furin cleavage site and 2A peptide sequence.

6. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule further encodes an immunoglobulin (Ig) signal peptide.

7. The nucleic acid molecule of claim 6 , wherein the Ig signal peptide comprises an IgE signal peptide.

8. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises an expression vector.

9. A composition comprising the nucleic acid molecule of claim 1 .

10. The composition of claim 9 further comprising a pharmaceutically acceptable excipient.

11. A method of treating or preventing an infection by Chikungunya virus (CHIKV), the method comprising administering
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence having at least 90% identity to the nucleotide sequence that encodes SEQ ID NO: 65; or
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence encoding an amino acid sequence having at least 90% identity to SEQ ID NO: 66.

12. A method of treating or preventing an infection by Dengue virus (DENV), the method comprising administering
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 67;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 69;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 71;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 73;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 75;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence having at least 90% identity to a nucleotide sequence that encodes SEQ ID NO: 77;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence encoding amino acid sequence having at least 90% identity to SEQ ID NO:68;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence encoding amino acid sequence having at least 90% identity to SEQ ID NO:70;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence encoding amino acid sequence having at least 90% identity to SEQ ID NO:72;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence encoding amino acid sequence having at least 90% identity to SEQ ID NO:74;
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence encoding amino acid sequence having at least 90% identity to SEQ ID NO:76; or
a nucleic acid molecule encoding a synthetic antibody comprising a nucleic acid sequence encoding amino acid sequence having at least 90% identity to SEQ ID NO:78.

13. The method of claim 11 , wherein administering includes at least one of electroporation and injection.

14. The method of claim 12 , wherein administering includes at least one of electroporation and injection.

Assignees

• Univ Pennsylvania
• Inovio Pharmaceuticals Inc

Inventors

• Weiner David
• Muthumani Karuppiah
• Flingai Seleeke
• Sardesai Niranjan

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/116 Primary

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• A61P31/14

  for RNA viruses · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title